Does Combination Menopausal Hormone Therapy Increase the Risk of Breast Cancer?

In 2002, researchers from the Women’s Health Initiative (WHI) reported that menopausal hormone therapy (MHT) increases the risk of breast cancer. This widely publicized finding led […]

What Should Frontline Treatment Be in Chronic Myeloid Leukemia?

The US Food and Drug Administration has approved 3 tyrosine kinase inhibitors (TKIs) for use as frontline treatment in chronic myeloid leukemia (CML): imatinib, dasatinib (Sprycel, […]

Should Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Be Intensive?

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Counterpoints: Approximately 20% to 30% of adults diagnosed with acute lymphoblastic leukemia are positive […]

What Should Standard Frontline Therapy Be in Older Patients With Chronic Lymphocytic Leukemia?

Clinical Advances in Hematology & Oncology Volume 14, Issue 5, May 2016 Jennifer A. Woyach, MD, vs Clemens-Martin Wendtner, MD Now that ibrutinib (Imbruvica, Pharmacyclics/Janssen), a […]

Should EGFR Tyrosine Kinase Inhibitors Be Used in Non–Small Cell Lung Cancer in the Absence of EGFR Mutations?

Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1 Tyrosine kinase inhibitors (TKIs) that block epidermal growth factor receptor (EGFR) clearly work […]

Should All Patients With SCLC Receive Prophylactic Cranial Irradiation If They Have Responded to Treatment?

Clinical Advances in Hematology & Oncology November 2015, Volume 13, Issue 11 Ben J. Slotman, MD, PhD vs Jacob Yousef, BS, and Henry Wagner, MD Brain […]

Is There a Clinical Role for Molecular Phenotyping in Atypical Presentation of Metastatic Castration-Resistant Prostate Cancer?

Now that our understanding of potentially actionable mutations has increased, is it time for physicians to look into molecular phenotyping for their patients with metastatic castration-resistant […]

Which Should Be Used First in Symptomatic Metastatic Castration-Resistant Prostate Cancer, Docetaxel or Radium?

Clinical Advances in Hematology & Oncology May 2015, Volume 13, Issue 5 It is not unusual for metastatic prostate cancer to progress despite treatment with abiraterone […]

Counterpoints: Do Patients With Multiple Myeloma Need Maintenance Treatment?

Clinical Advances in Hematology & Oncology March 2015, Volume 13, Issue 3 Multiple myeloma is an incurable disease, and patients who respond to treatment eventually […]

Counterpoints: Is Proton Beam Therapy Better Than Standard Radiation Therapy?

Clinical Advances in Hematology & oncology December 2014, Volume 12, Issue 12 Is Proton Beam Therapy Better Than Standard Radiation Therapy? Proton beam therapy has […]

Targeted Therapy vs Chemotherapy: Which Has Had More Impact on Survival in Lung Cancer?

Clinical Advances in Hematology & Oncology November 2014, Volume 12, Issue 11 Chemotherapy and targeted therapy both have earned their place in the treatment of lung […]

Should Lung Cancer Screening With Low-Dose Computed Tomography Be Routine for Smokers and Former Smokers?

Clinical Advances in Hematology & Oncology October 2014, Volume 12, Issue 10 The U.S. Preventive Services Task Force (USPSTF) gave a grade of B to low-dose […]

Is Maintenance Therapy Necessary in Low-Grade Lymphoma?

Clinical Advances in Hematology & Oncology August 2014, Volume 12, Issue 8 Maintenance therapy with rituximab has been shown to prolong progression-free survival and event-free survival in […]

Screening Mammography: Do the Benefits Always Outweigh the Harms?

Clinical Advances in Hematology & Oncology June 2014, Volume 12, Issue 6 “Mammography saved my life” is a common refrain from women who have been screened and […]

To Transplant or Not To Transplant in Multiple Myeloma

Clinical Advances in Hematology & Oncology May 2014, Volume 12, Issue 5 High-dose therapy in combination with autologous stem cell transplantation (ASCT) has become the standard […]

Counterpoints: Can Radiotherapy Be Omitted in Patients With Localized Hodgkin Lymphoma?

Clinical Advances in Hematology & Oncology April 2014, Volume 12, Issue 4 Radiation therapy has a dramatic effect on lymphomas, and has played an important role in […]

Why Are Cancer Drugs So Costly?

Clinical Advances in Hematology & Oncology January 2014, Volume 12, Issue 1 The cost of cancer drugs is at an all-time high, with several lifesaving agents costing […]